文献速递心脑血管急症

氯吡格雷与阿司匹林单药治疗用于经皮冠状动脉介入治疗后高心血管事件风险患者的疗效与安全性(SMART-CHOICE 3):一项随机、开放标签、多中心试验

Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
PubMed 文献 · Lancet · 2025-03-30
一句话结论PCI后完成标准双联抗血小板疗程的高缺血风险患者,氯吡格雷单药较阿司匹林单药显著降低死亡、心肌梗死或卒中复合终点(3年发生率4.4% vs 6.6%,HR 0.71),出血风险无差异。

本研究为多中心、随机、开放标签试验,纳入完成标准双联抗血小板疗程后PCI(药物洗脱支架)且高复发缺血风险(既往心肌梗死、药物治疗的糖尿病或复杂冠脉病变)的患者5506例,1:1随机接受氯吡格雷75 mg每日一次或阿司匹林100 mg每日一次口服单药治疗。主要终点为全因死亡、心肌梗死或卒中的复合终点,氯吡格雷组92例、阿司匹林组128例(3年累积发生率4.4% vs 6.6%,HR 0.71,95%CI 0.54-0.93,p=0.013)。心肌梗死发生率氯吡格雷组低于阿司匹林组(1.0% vs 2.2%,HR 0.54,95%CI 0.33-0.90),出血风险两组无差异(3.0% vs 3.0%,HR 0.97,95%CI 0.67-1.42)。作者认为,在高缺血风险且完成标准DAPT的PCI后患者中,氯吡格雷单药较阿司匹林单药显著降低复合终点且不增加出血。

要点

  • PCI后完成标准DAPT的高缺血风险患者(既往心肌梗死、药物治疗的糖尿病或复杂冠脉病变),氯吡格雷75 mg每日一次较阿司匹林100 mg每日一次降低3年死亡、心肌梗死或卒中复合终点(4.4% vs 6.6%,HR 0.71,95%CI 0.54-0.93)。
  • 心肌梗死3年发生率氯吡格雷组1.0% vs 阿司匹林组2.2%(HR 0.54,95%CI 0.33-0.90),氯吡格雷组更低。
  • 全因死亡3年发生率氯吡格雷组2.4% vs 阿司匹林组4.0%(HR 0.71,95%CI 0.49-1.02),置信区间跨1,未达统计学显著。
  • 出血风险两组无差异(3年发生率3.0% vs 3.0%,HR 0.97,95%CI 0.67-1.42),氯吡格雷未增加任何不良事件发生率。
  • 卒中3年发生率氯吡格雷组1.3% vs 阿司匹林组1.3%(HR 0.79,95%CI 0.46-1.36),无显著差异。

适用人群与场景

  • 年龄19岁及以上、PCI(药物洗脱支架)后完成标准双联抗血小板疗程、高复发缺血事件风险(既往心肌梗死、药物治疗的糖尿病或复杂冠脉病变)的患者。
  • 研究在韩国26个中心进行,随机化距PCI中位时间17.5个月(IQR 12.6-36.1个月)。

诊断标准与关键阈值

  • 高复发缺血事件风险定义:既往心肌梗死(入组前任何时间)、药物治疗的糖尿病或复杂冠脉病变。
  • 纳入条件:完成PCI后标准疗程双联抗血小板治疗。

处置流程与药物剂量

  • 氯吡格雷75 mg口服每日一次单药治疗。
  • 阿司匹林100 mg口服每日一次单药治疗。
  • 随机化距PCI中位时间17.5个月(IQR 12.6-36.1个月),中位随访2.3年(IQR 1.6-3.0)。

研究设计与关键结果

  • 多中心、随机、开放标签试验,26个中心,5506例患者随机(氯吡格雷组2752例,阿司匹林组2754例),中位随访2.3年(IQR 1.6-3.0)。
  • 主要终点(全因死亡、心肌梗死或卒中复合终点):氯吡格雷组92例 vs 阿司匹林组128例,3年累积发生率4.4%(95%CI 3.4-5.4) vs 6.6%(95%CI 5.4-7.8),HR 0.71(95%CI 0.54-0.93),p=0.013。
  • 全因死亡:氯吡格雷组50例 vs 阿司匹林组70例,3年发生率2.4%(95%CI 1.6-3.1) vs 4.0%(95%CI 2.9-5.0),HR 0.71(95%CI 0.49-1.02)。
  • 心肌梗死:氯吡格雷组23例 vs 阿司匹林组42例,3年发生率1.0%(95%CI 0.6-1.4) vs 2.2%(95%CI 1.4-2.9),HR 0.54(95%CI 0.33-0.90)。
  • 卒中:氯吡格雷组23例 vs 阿司匹林组29例,3年发生率1.3%(95%CI 0.7-2.0) vs 1.3%(95%CI 0.8-1.7),HR 0.79(95%CI 0.46-1.36)。
  • 出血:氯吡格雷组3.0%(95%CI 2.0-3.9) vs 阿司匹林组3.0%(95%CI 2.2-3.9),HR 0.97(95%CI 0.67-1.42)。
  • 氯吡格雷与阿司匹林相比,任何不良事件发生率未升高。

证据类型、等级与局限

  • 证据类型:随机、开放标签、多中心试验。
  • 试验注册号:ClinicalTrials.gov NCT04418479;已停止入组,延长随访正在进行中。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于PCI后完成标准双联抗血小板疗程的高缺血风险患者(既往心肌梗死、药物治疗的糖尿病或复杂冠脉病变),作者认为氯吡格雷单药较阿司匹林单药显著降低全因死亡、心肌梗死和卒中复合终点,且不增加出血风险。
  • 氯吡格雷75 mg每日一次与阿司匹林100 mg每日一次均为口服单药方案,本研究为开放标签设计。

指南或共识出处

  • SMART-CHOICE 3试验,发表于Lancet,ClinicalTrials.gov注册号NCT04418479。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal strategy for long-term antiplatelet maintenance for patients who underwent percutaneous coronary intervention (PCI) remains uncertain. This study aimed to compare the efficacy and safety of clopidogrel versus aspirin monotherapy in patients who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI with drug-eluting stents.

METHODS: In this multicentre, randomised, open-label trial, patients aged 19 years or older at high risk of recurrent ischaemic events (previous myocardial infarction at any time before enrolment, medication-treated diabetes, or complex coronary lesions) who completed a standard duration of DAPT after PCI were randomly assigned (1:1) to receive clopidogrel (75 mg once a day) or aspirin (100 mg once a day) oral monotherapy at 26 sites in South Korea. The primary endpoint was the cumulative incidence of a composite of death from any cause, myocardial infarction, or stroke, assessed in the intention-to-treat population. Adverse events were captured as part of the secondary endpoints. This trial is registered with ClinicalTrials.gov (NCT04418479). It is closed to accrual and extended follow-up is ongoing.

FINDINGS: Between Aug 10, 2020, and July 31, 2023, 5542 patients were assessed for eligibility and 5506 were randomly assigned (2752 to clopidogrel monotherapy and 2754 to aspirin monotherapy). The median time between PCI and randomisation was 17·5 months (IQR 12·6-36·1 months). During a median follow-up period of 2·3 years (IQR 1·6-3·0), the primary endpoint occurred in 92 patients in the clopidogrel group and 128 patients in the aspirin group (Kaplan-Meier estimated 3-year incidence 4·4% [95% CI 3·4-5·4] vs 6·6% [5·4-7·8]; hazard ratio 0·71 [95% CI 0·54-0·93]; p=0·013). Death from any cause occurred in 50 patients in the clopidogrel group and 70 in the aspirin group (2·4% [1·6-3·1] vs 4·0% [2·9-5·0] at 3 years; 0·71 [0·49-1·02]); myocardial infarction in 23 patients in the clopidogrel group and 42 in the aspirin group (1·0% [0·6-1·4] vs 2·2% [1·4-2·9] at 3 years; 0·54 [0·33-0·90]); and stroke in 23 in the clopidogrel group and 29 in the aspirin group (1·3% [0·7-2·0] vs 1·3% [0·8-1·7] at 3 years; 0·79 [0·46-1·36]). There was no difference in the risk of bleeding between the clopidogrel and aspirin groups (3·0% [2·0-3·9] vs 3·0% [2·2-3·9] at 3 years; 0·97 [0·67-1·42]). Clopidogrel was not associated with a higher incidence of any adverse event compared with aspirin.

INTERPRETATION: Among patients who were at high risk of recurrent ischaemic events and who completed the standard duration of DAPT following PCI, clopidogrel monotherapy, compared with aspirin monotherapy, significantly reduced the cumulative incidence of a composite of death from any cause, myocardial infarction, and stroke, without an apparent increase in the risk of bleeding.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Choi KH, Park YH, Lee JY, et al. Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial. Lancet. 2025. PMID: 40174599. doi:10.1016/S0140-6736(25)00449-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。